94 related articles for article (PubMed ID: 30155590)
1. Guest editorial: chronic myeloid leukemia.
Minami Y
Int J Hematol; 2018 Oct; 108(4):353-354. PubMed ID: 30155590
[No Abstract] [Full Text] [Related]
2. The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia.
Fernandes RS; Gorman AM; McGahon A; Lawlor M; McCann S; Cotter TG
Leukemia; 1996 Jun; 10 Suppl 2():s17-21. PubMed ID: 8649049
[TBL] [Abstract][Full Text] [Related]
3. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
4. Therapy-free remission in chronic myeloid leukemia: possible mechanism.
Gale RP; Hochhaus A
Expert Rev Hematol; 2018 Apr; 11(4):269-272. PubMed ID: 29448857
[No Abstract] [Full Text] [Related]
5. Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model.
Halbach S; Köhler M; Uhl FM; Huber J; Zeiser R; Koschmieder S; Aumann K; Brummer T
Leukemia; 2016 Sep; 30(9):1942-5. PubMed ID: 27125306
[No Abstract] [Full Text] [Related]
6. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
[TBL] [Abstract][Full Text] [Related]
7. The biology of chronic myeloid leukemia.
Faderl S; Talpaz M; Estrov Z; O'Brien S; Kurzrock R; Kantarjian HM
N Engl J Med; 1999 Jul; 341(3):164-72. PubMed ID: 10403855
[No Abstract] [Full Text] [Related]
8. Oxidative damage and cell signaling transduction in patients of chronic myeloid leukemia.
Pande D; Negi R; Karki K; Khanna RS; Khanna HD
Acta Biochim Biophys Sin (Shanghai); 2015 Jun; 47(6):474-6. PubMed ID: 25921413
[No Abstract] [Full Text] [Related]
9. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.
Haririan M; Kaviani S; Soleimani M; Ghaemi SR; Delalat B; Atashi A
Hematology; 2012 Jan; 17(1):28-34. PubMed ID: 22549445
[TBL] [Abstract][Full Text] [Related]
10. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
11. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
[TBL] [Abstract][Full Text] [Related]
12. Interphase FISH studies of chronic myeloid leukemia.
Dewald GW
Methods Mol Biol; 2002; 204():311-42. PubMed ID: 12397807
[No Abstract] [Full Text] [Related]
13. Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline.
Molica M; Zacheo I; Diverio D; Alimena G; Breccia M
Br J Haematol; 2015 Apr; 169(1):148-50. PubMed ID: 25296902
[No Abstract] [Full Text] [Related]
14. Chronic myelogenous leukemia: from pathogenesis to therapy.
Verfaillie CM
J Hematother; 1999 Feb; 8(1):3-13. PubMed ID: 10192297
[No Abstract] [Full Text] [Related]
15. The small problem when treating childhood chronic myeloid leukemia.
Suttorp M
Pediatr Hematol Oncol; 2019 May; 36(4):187-188. PubMed ID: 31271344
[No Abstract] [Full Text] [Related]
16. Chronic myelogenous leukemia--the unfolding saga.
Goldman JM; Grosveld G; Baltimore D; Gale RP
Leukemia; 1990 Mar; 4(3):163-7. PubMed ID: 2179637
[No Abstract] [Full Text] [Related]
17. [Chronic myeloid leukosis. Current status].
Cervantes F
An Med Interna; 1991 Jun; 8 Suppl 2():14-7. PubMed ID: 1878465
[No Abstract] [Full Text] [Related]
18. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
Zhang JH; He YL; Zhu R; Du W; Xiao JH
Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous anaplastic large-cell lymphoma occurring in a case of chronic myeloid leukemia in remission.
Charafeddine KM; Farchoukh LO; Khalifeh I
J Cutan Pathol; 2012 Sep; 39(9):884-6. PubMed ID: 22775801
[No Abstract] [Full Text] [Related]
20. Synthetic small interfering RNAs reduce bcr-abl gene expression in leukaemic cells of de novo Philadelphia(+) acute myeloid leukaemia.
Koldehoff M; Steckel NK; Beelen DW; Elmaagacli AH
Clin Exp Med; 2006 Mar; 6(1):45-7. PubMed ID: 16550344
[No Abstract] [Full Text] [Related]
[Next] [New Search]
